Gufic Biosciences invested USD 50,000 in Selvax Pty Ltd, acquiring 378,350 shares at AUD 0.20 per share on April 28, 2026.
The investment is a strategic move to diversify into biotechnology and develop novel immunology-based cancer treatments.
Selvax is an Australian biopharma R&D company focused on immunotherapy for solid tumours in humans and dogs.
The transaction is completed, not a related party transaction, and increases Gufic's total holding to 1,685,350 ordinary shares.